Identifying Subgroup at High Risk of Transarterial Chemoembolization Failure Among Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
Authors:
- Edoardo PoliEPEdoardo Poli
- Marc-Antoine AllardMAMarc-Antoine Allard
- Astrid Laurent-BellueALAstrid Laurent-Bellue
- Maïté LewinMLMaïté Lewin
- Catherine GuettierCGCatherine Guettier
- Daniel AzoulayDADaniel Azoulay
- Audrey CoillyACAudrey Coilly
- Alexandre Dos SantosASAlexandre Dos Santos
- Jamila FaivreJFJamila Faivre
- Eric VibertEVEric Vibert
- Alina PascaleAPAlina Pascale
- Clara Prud’hommeCPClara Prud’homme
Open Access
Abstract
Background/Objectives: Transarterial chemoembolization (TACE) is the most widely used bridging treatment for hepatocellular carcinoma (HCC) before liver transplantation (LT) but may be associated with dropout and post-LT HCC recurrence. We aimed to identify a subgroup of HCC LT candidates at high risk of TACE-to-LT strategy failure (TLSF). Methods: All consecutive HCC LT candidates with French AFP-scores ≤ 2 who underwent at least one bridging TACE at Paul Brousse Hospital in 2013–2018 were included (n = 173). Dropout for HCC progression during waiting list and post-LT HCC recurrence was defined TLSF. Results: The one-year TLSF cumulative incidence was 15%. According to univariate analysis, pre-TACE AFP > 15 ng/mL was the only factor associated with decreased overall survival (OS) and TLSF-free survival (TLSF-FS) after the first TACE. The absence of complete radiological response (CRR) or pre-TACE AFP > 15 ng/mL were associated with reduced OS and TLSF-FS after a second TACE (n = 118). The cumulative incidence of TLSF reached 41% one year after the second TACE in patients with both AFP > 15 ng/mL and no CRR, while it was 7% for others (p < 0.001). Conclusions: HCC patients receiving bridging TACE, with pre-TACE AFP > 15 ng/mL and no CRR after two TACEs, are at high risk of delisting for HCC progression or of post-LT recurrence. Alternative therapeutic strategies should be proposed early for this better-defined population.Keywords
This publication has 42 references indexed in Scilit:
- Long-term survival and postoperative complications of pre-liver transplantation transarterial chemoembolisation in hepatocellular carcinoma: A systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2022
- The Intention‐to‐Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver TransplantationLiver Transplantation, 2019
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- Intention‐to‐treat survival benefit of liver transplantation in patients with hepatocellular cancerHepatology, 2017
- Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver TransplantJAMA Oncology, 2017
- Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular CarcinomaJAMA Oncology, 2015
- Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteriaHepatology, 2015
- Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantationLiver Transplantation, 2013
- How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE?Journal of Hepatology, 2013
- Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantationLiver Transplantation, 2011